EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Pharmacological effects of cardamonin in metabolic diseases: a review on preclinical studies

Aizhi Zhang, AbdulRahman Muthanna, Yu Zhao Lee, Xuan Xin Yew, Rieyshmondraj Selvanathan, Zuo Shan Reuel Gan, Ji Wei Tan, Yu-Cheng Ho, Ming Tatt Lee, Chau Ling Tham

Inflammopharmacology · 2026-04 · 34 (4) · 2317-2335

DOI: 10.1007/s10787-026-02191-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Inflammopharmacology, online erschienen am 21.03.2026. Verfasst von Aizhi Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia. Hauptthemen laut MEDLINE: Chalcones, Metabolic Diseases. Die Arbeit nennt 78 Literaturangaben. Gefördert von: National Science and Technology Council, UCSI University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardamonin (2’,4’-dihydroxy-6’-methoxychalcone) is a naturally occurring chalcone primarily isolated from Boesenbergia rotunda and Alpinia species, which has gained considerable attention for its diverse pharmacological properties. This comprehensive review examines the preclinical evidence supporting cardamonin’s therapeutic potential in metabolic diseases, including obesity, diabetes, cardiovascular complications, and related disorders. Preclinical studies have demonstrated that cardamonin exerts anti-inflammatory, antioxidant, and metabolic regulatory effects through modulation of key signaling pathways including NF-κB, Nrf2, AMPK, mTOR, and PPAR pathways. In obesity models, cardamonin suppresses lipogenesis and promotes browning of adipocytes via PKA-mediated mechanisms. In diabetes, it enhances glucose uptake through GLUT4 translocation and improves insulin sensitivity by inhibiting mTOR/S6K1 feedback. Cardamonin also demonstrates cardioprotective effects against ischemia-reperfusion injury, pressure overload, and doxorubicin-induced cardiotoxicity. Additionally, it shows nephroprotective properties in models of renal injury and metabolic dysfunction. However, clinical studies remain limited, and the therapeutic translation of cardamonin requires further investigation of its bioavailability, pharmacokinetics, and safety profile in humans. This review synthesizes current preclinical evidence and identifies critical gaps that warrant future research to establish cardamonin as a potential therapeutic agent for metabolic diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChalconesMetabolic DiseasesHumansAnimalsSignal TransductionAntioxidantsAnti-Inflammatory Agents

Stichwörter der Autor:innen

AntioxidantCardamoninCardiovascular diseaseDiabetes mellitusGood health and wellbeingObesity

Substanzen

cardamoninChalconesAntioxidantsAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia.
  • Department of Critical Care, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi , China.
  • Office of Postgraduate Studies, UCSI University, Kuala Lumpur, Malaysia.
  • Faculty of Medicine and Health Sciences, UCSI University, Kuala Lumpur, Malaysia.
  • Department of Biomedical Sciences, Faculty of Medicine, Nursing & Health Sciences, SEGi University, Selangor, Malaysia.
  • School of Science, Monash University Malaysia, Selangor, Malaysia.

Förderung

  • National Science and Technology Council
  • UCSI University

Zitieren

APA

Zhang, A., Muthanna, A., Lee, Y. Z., Yew, X. X., Selvanathan, R., Gan, Z. S. R., Tan, J. W., Ho, Y. C., Lee, M. T., & Tham, C. L. (2026). Pharmacological effects of cardamonin in metabolic diseases: a review on preclinical studies. Inflammopharmacology, 34(4), 2317-2335. https://doi.org/10.1007/s10787-026-02191-9

Vancouver

Zhang A, Muthanna A, Lee YZ, Yew XX, Selvanathan R, Gan ZSR, et al. Pharmacological effects of cardamonin in metabolic diseases: a review on preclinical studies. Inflammopharmacology. 2026;34(4):2317-2335. doi:10.1007/s10787-026-02191-9

BibTeX
@article{Zhang2026,
  author = {Zhang, Aizhi and Muthanna, AbdulRahman and Lee, Yu Zhao and Yew, Xuan Xin and Selvanathan, Rieyshmondraj and Gan, Zuo Shan Reuel and Tan, Ji Wei and Ho, Yu-Cheng and Lee, Ming Tatt and Tham, Chau Ling},
  title = {Pharmacological effects of cardamonin in metabolic diseases: a review on preclinical studies},
  journal = {Inflammopharmacology},
  year = {2026},
  volume = {34},
  number = {4},
  pages = {2317--2335},
  doi = {10.1007/s10787-026-02191-9}
}
Kostenlos starten →